GOSSAMER BIO, INC. (GOSS) Current Ratio
- Current ratio · latest quarter: Value 0.53×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.53× | Current assets / current liabilities. $72.72M ÷ $137.78M ≈ 0.53× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 72.72M USD | Assets, Current |
| Current obligations | 137.78M USD | Liabilities, Current |
| Cash and equivalents | 41.15M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 15.88M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 6.11M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 5.95M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $72.72M | $137.78M | $41.15M | $15.88M | $6.11M | (m) | $5.95M | (m) | 0.53× |
| 2026-03-31 | $124.54M | $56.51M | $41.03M | $58.19M | $9.25M | (m) | $10.82M | (m) | 2.20× |
| 2025-12-31 | $167.64M | $63.44M | $37.73M | $99.20M | $12.23M | (m) | $5.96M | (m) | 2.64× |
| 2025-09-30 | $203.99M | $62.12M | $8.93M | $171.29M | $9.24M | (m) | $1.12M | (m) | 3.28× |
| 2025-06-30 | $235.90M | $53.59M | $26.31M | $186.61M | $7.58M | (m) | $1.88M | (m) | 4.40× |
| 2025-03-31 | $275.48M | $48.22M | $29.02M | $228.91M | $6.58M | (m) | $3.39M | (m) | 5.71× |
| 2024-12-31 | $309.89M | $45.01M | $46.07M | $248.44M | $5.34M | (m) | $2.32M | (m) | 6.88× |
| 2024-09-30 | $344.27M | $51.09M | $28.46M | $298.57M | $6.59M | (m) | $3.06M | $0.00 | 6.74× |
| 2024-06-30 | $370.90M | $45.19M | $86.88M | $267.61M | $3.63M | (m) | $1.00M | $0.00 | 8.21× |
| 2024-03-31 | $255.27M | $35.82M | $38.86M | $205.53M | (m) | (m) | $2.66M | $9.59M | 7.13× |
| 2023-12-31 | $306.52M | $51.60M | $32.11M | $264.32M | $0.00 | (m) | $5.53M | $11.61M | 5.94× |
| 2023-09-30 | $341.49M | $42.32M | $82.61M | $246.28M | (m) | (m) | $1.25M | $11.61M | 8.07× |
| 2023-06-30 | $173.38M | $40.14M | $37.00M | $125.12M | (m) | (m) | $2.21M | $11.61M | 4.32× |
| 2023-03-31 | $210.41M | $40.57M | $65.24M | $136.61M | (m) | (m) | $2.73M | $11.61M | 5.19× |
| 2022-12-31 | $261.88M | $49.23M | $111.97M | $143.71M | (m) | (m) | $1.46M | $11.61M | 5.32× |
| 2022-09-30 | $312.03M | $52.65M | $153.48M | $150.91M | (m) | (m) | $363.00K | (m) | 5.93× |
| 2022-06-30 | $232.68M | $44.41M | $94.32M | $127.84M | (m) | (m) | $3.91M | (m) | 5.24× |
| 2022-03-31 | $280.77M | $34.57M | $138.91M | $132.72M | (m) | (m) | $592.00K | (m) | 8.12× |
| 2021-12-31 | $331.78M | $39.86M | $183.40M | $141.81M | (m) | (m) | $3.24M | $0.00 | 8.32× |
| 2021-09-30 | $373.99M | $35.90M | $213.47M | $152.55M | (m) | (m) | $1.19M | (m) | 10.42× |
| 2021-06-30 | $416.99M | $29.98M | $342.45M | $63.47M | (m) | (m) | $895.00K | (m) | 13.91× |
| 2021-03-31 | $465.85M | $29.44M | $439.66M | $13.64M | (m) | (m) | $1.07M | (m) | 15.82× |
| 2020-12-31 | $522.32M | $38.65M | $486.06M | $26.57M | (m) | (m) | $7.51M | (m) | 13.51× |
| 2020-09-30 | $566.21M | $32.61M | $461.96M | $93.42M | (m) | (m) | $865.00K | (m) | 17.36× |
| 2020-06-30 | $608.40M | $27.54M | $486.06M | $114.30M | (m) | (m) | $222.00K | (m) | 22.09× |
| 2020-03-31 | $355.44M | $28.36M | $111.35M | $234.81M | (m) | (m) | $2.60M | (m) | 12.53× |
| 2019-12-31 | $409.32M | $36.92M | $135.03M | $266.74M | (m) | (m) | $956.00K | (m) | 11.09× |
| 2019-09-30 | $452.37M | $33.17M | $130.71M | $315.76M | (m) | (m) | $2.56M | (m) | 13.64× |
| 2019-06-30 | $489.59M | $27.51M | $148.50M | $315.50M | (m) | (m) | $3.03M | (m) | 17.80× |
| 2019-03-31 | $497.79M | $25.15M | $170.85M | $310.37M | (m) | (m) | $4.55M | (m) | 19.79× |
| 2018-12-31 | $231.95M | $20.40M | $105.22M | $123.44M | (m) | (m) | $2.18M | (m) | 11.37× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |